Australia markets closed

Soleno Therapeutics, Inc. (SLNO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.8010+0.0180 (+2.30%)
At close: 4:00PM EDT
0.8010 0.00 (0.00%)
Pre-market: 04:11AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.7830
Open0.7800
Bid0.0000 x 900
Ask0.0000 x 1800
Day's range0.7560 - 0.8110
52-week range0.7560 - 3.3600
Volume408,533
Avg. volume379,910
Market cap63.887M
Beta (5Y monthly)0.42
PE ratio (TTM)N/A
EPS (TTM)-0.3930
Earnings date08 Nov 2021 - 12 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.00
  • GlobeNewswire

    Soleno Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

    REDWOOD CITY, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 2:40 PM Eastern Time. A live audio webcast and replay of the presentation will be ava

  • GlobeNewswire

    Soleno Therapeutics to Participate in the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

    REDWOOD CITY, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on Monday, September 20, 2021 at 1:15 PM Eastern Time. A live audio webcast and replay of the presentation wil

  • GlobeNewswire

    Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of PWS following One Year Treatment with DCCR

    Figure 1 Change from Pre-DCCR HQ-CT Total Score After 13, 26, 39, and 52 Weeks Figure 2 Change in HQ-CT after 26 Weeks and 52 Weeks for DCCR Compared to PfPWS Statistically significant reduction in hyperphagia and all other PWS behavioral parameters in Study C602 Statistically significant improvements compared to natural history of PWS from the PATH for PWS Study On track for data submission to the FDA in Q3 2021 REDWOOD CITY, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc.